Patent Term Extension Application for HALAVEN™(eribulin mesylate), U.S. Patent No. 6,214,865

Docket ID: FDA-2011-E-0156
Agency: Food and Drug Administration (FDA)
Parent Agency: Department of Health and Human Services (HHS)
Status: OPEN
Docket Details open glossary dialog  
Related RINs: None
Related Dockets: None
Keyword(s): CDER, U.S. Patent No. 6,214,865, eribulin mesylate, HALAVEN, Patent Extension Application
Type: Nonrulemaking
Center: CDER
Docket Item Code: E

Primary Documents

View All  (8)
Comment Period Closed
Posted: 02/24/2015
ID: FDA-2011-E-0156-0008
Comment Period Closed
Posted: 12/27/2012
ID: FDA-2011-E-0156-0007
Comment Period Closed
Posted: 05/03/2012
ID: FDA-2011-E-0156-0006
Comment Period Closed
Posted: 04/18/2012
ID: FDA-2011-E-0156-0005
Comment Period Closed
Posted: 01/10/2012
ID: FDA-2011-E-0156-0004

Supporting Documents

No documents available.


No comments posted.

Comments Received*
*This count refers to the total comment/submissions received on this docket, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.